ArticleCytotechnology2000
Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture.
Article in Cytotechnology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Challenges and solutions in transitioning to animal-free standards: a comprehensive analysis of components in human cell-based developmental neurotoxicity assays.Frontiers in toxicology · 2026Review
- Generation of Clonal Cultures of Adherent or Suspension Cells Using Flat Sessile Drops for Assurance of Monoclonality.Biotechnology and bioengineering · 2025Article
- Serum-Free and Protein-Free Media for the Cultivation of Recombinant Chinese Hamster Ovary (CHO) Cell Lines.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Effects of modified-BHI medium on the growth and metabolites ofFood science and biotechnology · 2024Article
- Cultured meat in the European Union: Legislative context and food safety issues.Current research in food science · 2024Review
- A Beefy-R culture medium: Replacing albumin with rapeseed protein isolates.Biomaterials · 2023Article
- Article
- The role of protein hydrolysates in prolonging viability and enhancing antibody production of CHO cells.Applied microbiology and biotechnology · 2021Article
- AnStem cells international · 2021Review
- Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.Frontiers in cell and developmental biology · 2021Review
- Would 20 nm Filtered Fetal Bovine Serum-Supplemented Media Support Growth of CHO and HEK-293 Cells?ACS applied bio materials · 2020Article
- Clinical Trials of Limbal Stem Cell Deficiency Treated with Oral Mucosal Epithelial Cells.International journal of molecular sciences · 2020Review
- Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.Frontiers in immunology · 2019Article
- Influence of cell type and cell culture media on the propagation of foot-and-mouth disease virus with regard to vaccine quality.Virology journal · 2018Article
- Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction.Stem cell research & therapy · 2017Article
- Attachment, Growth, and Detachment of Human Mesenchymal Stem Cells in a Chemically Defined Medium.Stem cells international · 2016Article
- Therapeutic potential of human adipose-derived stem cells (ADSCs) from cancer patients: a pilot study.PloS one · 2014Article
- Serum-free media for the production of human mesenchymal stromal cells: a review.Cell proliferation · 2013Review
- Promotion of stem cell proliferation by vegetable peptone.Cell proliferation · 2009Article
- A T-flask based screening platform for evaluating and identifying plant hydrolysates for a fed-batch cell culture process.Cytotechnology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technical limitations and evolution of therapeuticapplications for cell culture-derived products haveaccelerated elimination of animal-derived constituentsto minimize inadvertent introduction of adventitiousviral or prion agents. Practical considerationsdemand adequate emphasis both on design of theserum-free/protein-free culture environment and onnutrient media manufacturing process controls. Protein components may be acceptable, given adequateattention to synthetic process, sourcing (e.g.,geographic location and endemicity, species andtissue/organ) and validated treatment method. Variousoptions exist for re-engineering of traditionalserum-free formulations (containing insulin,transferrin and other protein factors) withnon-protein substitutes. Caution must also beexercised with sourcing of non-protein additives,particularly amino acids and lipids, to avoidintroducing adventitious contaminants. Simpleguidelines facilitate adaptation, cryopreservation andrecovery of many cell types within a protein-freeculture environment. Scrupulous maintenance offacility and equipment and monitoring of processwater, air handling systems and technical personnelare required to ensure that approved raw materials arecorrectly formulated and dispensed. Validatedsanitization processes provide additional assuranceagainst cross-contamination from previous batches ina multi-use facility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.